May 28 |
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
|
May 14 |
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
|
May 9 |
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
|
May 6 |
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
|
May 5 |
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
|
May 3 |
Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
|
May 3 |
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
May 2 |
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
|
May 2 |
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
|
May 2 |
Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $1.13M misses by $0.27M
|